From: Vitamin C levels in patients with SARS-CoV-2-associated acute respiratory distress syndrome
Clinical characteristics | COVID-19 ARDS (n = 18) |
---|---|
Age (mean, standard deviation, years) | 59 ± 9 |
Male (n, %) | 7 (38) |
SOFA score (median, interquartile range, points) | 4 (1) |
APACHE II score (mean, standard deviation, points) | 16.2 ± 1.6 |
Interval between ICU admission and blood samples extraction for vitamin C measurement (mean, standard deviation, days) | 17.5 ± 1.7 |
Interval between intubation and blood samples extraction for vitamin C measurement (mean, standard deviation, days) | 17.5 ± 1.7 |
ARDS-related variables | |
PaO2/FIO2 at the time of vitamin C measurement (mean, standard deviation, mmHg) | 94.4 ± 5.9 |
PEEP (cmH2O) at the time of vitamin C measurement (median, interquartile range, points) | 13.6 (3) |
Neuromuscular blockade during ICU admission (n, %) | 18 (100) |
Prone position during ICU admission (n, %) | 17 (94) |
Renal failure | |
AKI (n, %) | 3/18 (16) |
AKI I (n, %) | 2/3 (66) |
AKI III (n, %) | 1/3 (33) |
CRRT (n, %) | 1/18 (6) |
COVID-19-related therapies | |
Antivirals (n, %) | 14 (77) |
Hydroxychloroquine (n, %) | 17 (94) |
Tocilizumab (n, %) | 13 (72) |
Methylprednisolone (n, %) | 10 (55) |
LMWH anticoagulant (n, %) | 8 (44) |
Outcomes | |
Length of ICU stay (mean, standard deviation, days) | 28.4 ± 3.4 |
Number of hospital survivors (n, %) | 18 (100) |